Medical Therapy. Adverse Effects or Lack of Adverse Effects

Pathophysiology and prevalence of high output heart failure in group 1 pulmonary hypertension

Yogesh N V Reddy 1, Robert P Frantz 2, William R Miranda 2, Revati Varma 2, Paul M Hassoun 3, Anna R Hemnes 4, Evelyn Horn 5, Jane A Leopold 6, Franz Rischard 7, Erika B Rosenzweig 8, Nicholas S Hill 9, Serpil C Erzurum 10, Gerald J Beck 11, Samar Farha 12, J Emanuel Finet 12, Christine Jellis 12, Deborah Kwon 12, Stephen Mathai 3, Margaret Park 12, W H Wilson Tang 12, Barry A Borlaug 2; PVDOMICS Study GroupMayo Clinic. Johns Hopkins University. Vanderbilt University Medical Center. Weill Cornell Medicine. Brigham and Women’s Hospital and […]

Pathophysiology and prevalence of high output heart failure in group 1 pulmonary hypertension Read More »

Systematic Review of the Application of Pulmonary Hypertension Treatments in Ventricular Septal Defect, Pulmonary Atresia, and Major Aortopulmonary Collateral Arteries

Keiichi Hirono, Keiko Uchida, Taku Ishii, Hidekazu Ishida, Shinichi Takatsuki, Hiroyuki Fukushima, Kei Inai, Susumu Hosokawa, Reina Ishizaki, Hirofumi Sawada, Naofumi F. Sumitomo, Ayako Chida-Nagai, Yuichi Ishikawa, Hirohiko Motoki, Atsushi Yao, Shigetoyo Kogaki, Hiroyuki Yamagishi, Shozaburo DoiToyama University Hospital. Tokyo Medical University. Institute of Science Tokyo. Osaka University Graduate School of Medicine. Toho University, Omori

Systematic Review of the Application of Pulmonary Hypertension Treatments in Ventricular Septal Defect, Pulmonary Atresia, and Major Aortopulmonary Collateral Arteries Read More »

Safety of a novel portable inhaled nitric oxide generator for therapy of persistent pulmonary hypertension in neonates: a case series study

Yao Zhu, Jiongzhi He, Miner Cai, Lijun Wen, Minxu LiDongguan Maternal and Child Health Care Hospital. First Affiliated Hospital of Jinan University.China Translational PediatricsTransl Pediatr 2025; 14: 3305-3317DOI: 10.21037/tp-2025-535 AbstractBackground: Persistent pulmonary hypertension of the newborn (PPHN) is a life-threatening emergency in neonatal intensive care. Traditional treatments such as cylinder-based nitric oxide (NO) delivery systems rely on

Safety of a novel portable inhaled nitric oxide generator for therapy of persistent pulmonary hypertension in neonates: a case series study Read More »

Interventions for preventing high altitude illness: Part 2. Less commonly-used drugs

Alejandro G Gonzalez Garay, Daniel Molano Franco, Víctor H Nieto Estrada, Arturo J Martí-Carvajal, Ingrid Arevalo-RodriguezNational Institute of Pediatrics.Mexico Cochrane Database of Systemic ReviewsCochrane Database Syst Rev 2018; 3: DOI: 10.1002/14651858.CD012983 AbstractBackground: High altitude illness (HAI) is a term used to describe a group of mainly cerebral and pulmonary syndromes that can occur during travel to elevations

Interventions for preventing high altitude illness: Part 2. Less commonly-used drugs Read More »

A prospective, multicenter, open-label, single-arm Phase 2 study to investigate the pharmacokinetics, safety, tolerability, and exploratory efficacy of selexipag in children with pulmonary arterial hypertension

Maurice Beghetti, Lene Nygaard Axelsen, Julian I. Borissoff, Mahdi Farhan, Simon Grill, Sining Leng, Alberto Russu, Catherine Lesage, Tatiana Remeňová, Shu-Fang Hsu Schmitz, Shahin MoledinaUniversity Hospitals of Geneva. Johnson & Johnson. Great Ormond Street Hospital. Switzerland and United Kingdom ChestChest 2025; DOI: 10.1016/j.chest.2025.12.013 AbstractBackground: Selexipag is an oral selective prostacyclin receptor agonist approved for treating pulmonary arterial

A prospective, multicenter, open-label, single-arm Phase 2 study to investigate the pharmacokinetics, safety, tolerability, and exploratory efficacy of selexipag in children with pulmonary arterial hypertension Read More »

Reduction in Prostacyclin Infusion Errors Following a Comprehensive Multidisciplinary Process Transformation for Hospitalized Pediatric Patients with Pulmonary Hypertension: A Quality Improvement Project

Christa Kirk, Anne Davis, Delphine YungDuquesne University School of Pharmacy. Seattle Children’s Hospital. University of Washington School of Medicine.United States Journal of Pediatric Pharmacology and TherapeuticsJ Pediatr Pharmacol Ther 2025; 30: 800-806DOI: 10.5863/JPPT-25-00033 AbstractObjective: Owing to a rise in potentially serious errors with parenteral prostacyclin infusions associated with using an unfamiliar MedFusion 3500 syringe pump (MedFusion), we

Reduction in Prostacyclin Infusion Errors Following a Comprehensive Multidisciplinary Process Transformation for Hospitalized Pediatric Patients with Pulmonary Hypertension: A Quality Improvement Project Read More »

Preparation of 18β-Glycyrrhetinic Acid Liposome and Its Therapeutic Effect on Pulmonary Arterial Hypertension

Yanmin Pei, Meidong Si, Xuemei Ma, Siyun Liu, Fang Zhao, Ru ZhouNingxia Medical University and General Hospital of Ningxia Medical University.China Drug Design, Development and TherapyDrug Des Dev Ther 2025; 19: 11119-11144DOI: 10.2147/DDDT.S547530 AbstractPurpose: 18β-Glycyrrhetinic acid liposomes (18β-GA-Lips) were developed to enhance lung-specific drug delivery and optimize the therapeutic management of pulmonary arterial hypertension (PAH).Methods: 18β-GA-Lips of varying

Preparation of 18β-Glycyrrhetinic Acid Liposome and Its Therapeutic Effect on Pulmonary Arterial Hypertension Read More »

Can Milrinone Be a Therapeutic Alternative in Persistent Pulmonary Hypertension of the Newborn? A Case Series and Narrative Review

Eliza Wasilewska, Norbert Dera, Łukasz Minarowski, Łukasz Osinski, Anna Doboszynska, Sławomir Szajda, Alina MinarowskaMedical University of Gdańsk. Center of Postgraduate Medical Education. Warsaw Institute of Women’s Health. Medical University of Bialystok. University Teaching Hospital. Regional Specialist Hospital in Olsztyn. University of Warmia and Mazury in Olsztyn. University of Warmia and Mazury. Children’s University Hospital in

Can Milrinone Be a Therapeutic Alternative in Persistent Pulmonary Hypertension of the Newborn? A Case Series and Narrative Review Read More »

Efficacy and Tolerability of Selexipag in Pediatric Patients with Pulmonary Arterial Hypertension: An Updated Systematic Review and Meta-analysis

Vasiliki Patsiou, Triantaphyllia Grantza, Thomas Chrysochoidis-Trantas, Maria Kavga, Nikolaos Fragakis, Antonio Ziakas, Alexandra Arvanitaki, George GiannakoulasAHEPA University General Hospital, Hippokrateion General Hospital and Aristotle University of Thessaloniki. Feinstein Institutes for Medical Research. Elmezzi Graduate School of Molecular Medicine and Northwell Health. Royal Brompton Hospital. Greece, United States and United Kingdom Pediatric CardiologyPediatr Cardiol 2025; DOI: 10.1007/s00246-025-04094-y

Efficacy and Tolerability of Selexipag in Pediatric Patients with Pulmonary Arterial Hypertension: An Updated Systematic Review and Meta-analysis Read More »

Early Oxygenation and Mortality in Infants Treated with Inhaled Nitric Oxide (iNO) for Persistent Pulmonary Hypertension of the Newborn (PPHN)

Marina S. Oren, Kikelomo Babata, June Hu, Venkatakrishna Kakkilaya, Patti J. Burchfield, Michelle Hagans, L. Steven Brown, Satyan Lakshminrusimha, Vishal KapadiaUniversity of Texas Southwestern Medical Center. Texas Health Presbyterian Hospital of Dallas. Parkland Health & Hospital System. University of California Davis Children’s Hospital.United States Journal of Pediatrics: Clinical PracticeJ Pediatr Clin Pract 2025; 18: DOI: 10.1016/j.jpedcp.2025.200189

Early Oxygenation and Mortality in Infants Treated with Inhaled Nitric Oxide (iNO) for Persistent Pulmonary Hypertension of the Newborn (PPHN) Read More »

Scroll to Top